Abstract
145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have